Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel Disease.

Date publication

mars 2026

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Dignass A, Narula N, Pratap K, Danese S, Dotan I, Iacucci M, Jairath V, Loftus EV, Magro F, Mantzaris G, Peyrin-Biroulet L, Rubin DT, Sands BE, Turner D, Reinisch W,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41802119

Résumé

Central reading of endoscopy and histopathology is the current standard for disease activity assessment in inflammatory bowel disease (IBD) clinical trials but is limited by inter- and intra-reader variability, operational delays, and cost. Artificial intelligence (AI) and machine learning (ML) offer the potential to improve accuracy, efficiency, and reproducibility. The International Organization for the Study of IBD (IOIBD) developed consensus statements on AI/ML use for endoscopic and histologic endpoint assessment in IBD trials.

Mots clés

Crohn’s disease, artificial intelligence, clinical trials, endoscopy, histology, inflammatory bowel disease, machine learning, ulcerative colitis

Référence

J Crohns Colitis. 2026 03 9;: